Unmet Needs and Future Directions in Inflammatory Eye Disease

REFERENCES

• Vigil EM, Sepah YJ, Watters AL, et al. Assessment of changes in quality-of-life among patients in the SAVE Study – Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. J Ophthalmic Inflamm Infect. 2015;5:13.
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST. Quality-of-life metrics in pediatric uveitis. Int Ophthalmol Clin. 2015;55:93–101.
   PubMedGoogle Scholar
• Jalil A, Yin K, Coyle L, et al. Vision-related quality-of-life and employment status in patients with uveitis of working age: a prospective study. Ocul Immunol Inflamm. 2012;20:262–265.
   PubMed Web of Science ®Google Scholar
• Fenwick EK, Pesudovs K, Khadka J, et al. The impact of diabetic retinopathy on quality-of-life: qualitative findings from an item bank development project. Qual Life Res. 2012;1:1771–1782.
   Google Scholar
• Hirai FE, Tielsch JM, Klein BE, et al. Ten-year change in vision-related quality-of-life in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology. 2011;118:353–358.
   PubMed Web of Science ®Google Scholar
• Frick KD, Drye LT, Kempen JH, et al. Associations among visual acuity and vision- and health-related quality-of-life among patients in the multicenter uveitis steroid treatment trial. Invest Ophthalmol Vis Sci. 2012;53:1169–1176.
   Google Scholar
• Miserocchi E, Modorati G, Mosconi P, et al. Quality-of-life in patients with uveitis on chronic systemic immunosuppressive treatment. Ocul Immunol Inflamm. 2010;18:297–304.
   PubMed Web of Science ®Google Scholar
• Saxena S, Carlson D, Billington R. The WHO quality-of-life assessment instrument (WHOQOL-Bref): the importance of its items for cross-cultural research. Qual Life Res. 2001;10:711–721.
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–263.
   PubMed Web of Science ®Google Scholar
• Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119:1050–1058.
   Google Scholar
• Patel V, Giesebrecht S, Burton AR, et al. Reliability revisited: autonomic responses in the context of everyday well-being. Int J Cardiol. 2013;166:743–745.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Sepah YJ, Watters A, et al. One-Year Outcomes of the SAVE study: sirolimus as a therapeutic approach for UVEitis. Transl Vis Sci Technol. 2015;4:4.
   PubMed Web of Science ®Google Scholar
• Comyn O, Lightman SL, Hykin PG. Corticosteroid intravitreal implants vs. ranibizumab for the treatment of vitreoretinal disease. Curr Opin Ophthalmol. 2013;24:248–254.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Lightman S, Drye L, et al. Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results. Ophthalmology. 2015;122:2351–2359.
   Web of Science ®Google Scholar
• Wakefield D, Chang JH, Amjadi S, et al. What is new HLA-B27 acute anterior uveitis? Ocul Immunol Inflamm. 2011;19:139–144.
   PubMed Web of Science ®Google Scholar
• Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 2005;50:364–388.
   PubMed Web of Science ®Google Scholar
• Robinson PC, Claushuis TA, Cortes A, et al. Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol. 2015;67:140–151.
   PubMed Web of Science ®Google Scholar
• Schittenhelm RB, Sian TC, Wilmann PG, et al. Revisiting the arthritogenic peptide theory: quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes. Arthritis Rheumatol. 2015;67:702–713.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Alessandro R, Triolo G. Response to: ‘IL-23 expression and activation of autophagy in synovium and PBMCs of HLA-B27 positive patients with ankylosing spondylitis’ by Neerinckx, et al. Ann Rheum Dis. 2014;73:e69.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Thurau S, Hennig M, et al. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:1531–1551.
   Google Scholar
• Lee RW, Nicholson LB, Sen HN, et al. Autoimmune and autoinflammatory mechanisms in uveitis. Semin Immunopathol. 2014;36:581–594.
   PubMed Web of Science ®Google Scholar
• Bakir-Gungor B, Remmers EF, Meguro A, et al. Identification of possible pathogenic pathways in Behcet’s disease using genome-wide association study data from two different populations. Eur J Hum Genet. 2015;23:678–687.
   PubMed Web of Science ®Google Scholar
• Gul A. Genetics of Behcet’s disease: lessons learned from genome-wide association studies. Curr Opin Rheumatol. 2014;26:56–63.
   PubMed Web of Science ®Google Scholar
• Schattner A. Review: In RA, standard- and high-dose biologic drugs increase serious infection compared with traditional DMARDs. Ann Intern Med. 2015;163:JC5.
   Google Scholar
• Huizinga T, Knevel R. Rheumatoid arthritis: 2014 treat-to-target RA recommendations–strategy is key. Nat Rev Rheumatol. 2015;11:509–511.
   PubMed Web of Science ®Google Scholar
• Trusko B, Thorne J, Jabs D, et al. The Standardization of Uveitis Nomenclature (SUN) project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52:259–265,S251–S256.
   PubMed Web of Science ®Google Scholar
• Herbort CP, Guex-Crosier Y, de Ancos E, et al. Use of laser flare photometry to assess and monitor inflammation in uveitis. Ophthalmology. 1997;104:64–71.
   PubMed Web of Science ®Google Scholar
• Bernasconi O, Papadia M, Herbort CP. Sensitivity of laser flare photometry compared to slit-lamp cell evaluation in monitoring anterior chamber inflammation in uveitis. Int Ophthalmol. 2010;30:495–500.
   PubMedGoogle Scholar
• Tappeiner C, Heinz C, Roesel M, et al. Elevated laser flare values correlate with complicated course of anterior uveitis in patients with juvenile idiopathic arthritis. Acta Ophthalmol. 2011;89:e521–e527.
   PubMed Web of Science ®Google Scholar
• Davis JL, Madow B, Cornett J, et al. Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol. 2010;150:637–641.
   PubMed Web of Science ®Google Scholar
• Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17:160–169.
   PubMed Web of Science ®Google Scholar
• Ahmadzai H, Wakefield D, Thomas PS. The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques. Inflammopharmacology. 2011;19:55–68.
   PubMedGoogle Scholar
• Ahmadzai H, Cameron B, Chui J, et al. Measurement of neopterin, TGF-beta1 and ACE in the exhaled breath condensate of patients with sarcoidosis. J Breath Res. 2013;7:046003.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Hatef E, Kayen B, et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology. 2011;118:184–190.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008;15:47–55.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121:1863–1870.
   Google Scholar
• Ossewaarde-van Norel A, Rothova A. Clinical review: update on treatment of inflammatory macular edema. Ocul Immunol Inflamm. 2011;19:75–83.
   PubMed Web of Science ®Google Scholar
• de Boer J, Steijaert A, van den Bor R, et al. Development of macular edema and impact on visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2015;23:67–73.
   PubMed Web of Science ®Google Scholar
• Rossetto JD, Nascimento H, Fernandes DD, et al. Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant. Arq Bras Oftalmol. 2015;78:190–193.
   PubMed Web of Science ®Google Scholar
• Gregory AC, 2nd, Kempen JH, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120:186–192.
   PubMed Web of Science ®Google Scholar
• Wakefield D, Abu El-Asrar A, McCluskey P. Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy. Ocul Immunol Inflamm. 2012;20:277–287.
   PubMed Web of Science ®Google Scholar
• Reeves SW, Sloan FA, Lee PP, et al. Uveitis in the elderly: epidemiological data from the national long-term care survey Medicare cohort. Ophthalmology. 2006;113:307.
   PubMed Web of Science ®Google Scholar
• Gregoire MA, Kodjikian L, Varron L, et al. Characteristics of uveitis presenting for the first time in the elderly: analysis of 91 patients in a tertiary center. Ocul Immunol Inflamm. 2011;19:219–226.
   PubMed Web of Science ®Google Scholar
• Zamiri P, Boyd S, Lightman S. Uveitis in the elderly–is it easy to identify the masquerade? Br J Ophthalmol. 1997;81:827–831.
   PubMed Web of Science ®Google Scholar
• Barton K, Pavesio CE, Towler HM, et al. Uveitis presenting de novo in the elderly. Eye (Lond). 1994;8:288–291.
   PubMed Web of Science ®Google Scholar
• Gabardi S, Tullius SG, Krenzien F. Understanding alterations in drug handling with aging: a focus on the pharmacokinetics of maintenance immunosuppressants in the elderly. Curr Opin Organ Transplant. 2015;20:424–430.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149:550–561.
   PubMed Web of Science ®Google Scholar
• Yates WB, McCluskey PJ, Wakefield D. Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy? J Ophthalmic Inflamm Infect. 2013;3:48.
   PubMedGoogle Scholar
• Yates WB, Vajdic CM, Na R, et al. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Ophthalmology. 2015;122:265–273.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2001;15:677–691.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42:1761–1766.
   PubMed Web of Science ®Google Scholar
• Avci AB, Feist E, Burmester GR. Biologicals in rheumatoid arthritis: current and future. RMD Open. 2015;1:e000127.
   PubMedGoogle Scholar
• Walker UA, Jaeger VK, Chatzidionysiou K, et al. Rituximab done: what’s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. Rheumatology (Oxford) 2015;55:230–236.
   PubMed Web of Science ®Google Scholar
• Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015;28:179–193.
   PubMed Web of Science ®Google Scholar
• Thompson IA, Liu B, Sen HN, et al. Association of complement factor H tyrosine 402 histidine genotype with posterior involvement in sarcoid-related uveitis. Am J Ophthalmol. 2013;155:1068–1074.
   PubMed Web of Science ®Google Scholar
• Chighizola CB, Favalli EG, Meroni PL. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. 2014;47:6–16.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum. 2010;62:2796–2805.
   Google Scholar
• Deuter C, Stubiger N, Zierhut M. Interferon-alpha therapy in noninfectious uveitis. Dev Ophthalmol. 2012;51:90–97.
   PubMedGoogle Scholar
• Deuter CM, Kotter I, Gunaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–913.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Gelisken F, Stubiger N, et al. Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases. Ocul Immunol Inflamm. 2011;19:216–218.
   PubMed Web of Science ®Google Scholar
• Trittibach P, Barker SE, Broderick CA, et al. Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. Gene Ther. 2008;15:1478–1488.
   PubMed Web of Science ®Google Scholar